NSC600684 - Moligand™ , Channel blocker of TRPV4, CAS No.N612413, Channel blocker of TRPV4

CAS: N612413 Cat. No.: N612413 PubChem CID: 353192
注文可能
GRADE & PURITY Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools.
Synonyms
NSC-600684
Storage
Room temperature
★
Size
USA
ドイツ (EU)*
Price
Qty
5mg
N612413-5mg
受注生産 · 8~12週間
$799.90
25mg
N612413-25mg
受注生産 · 8~12週間
$1,714.90
Enter a quantity for the sizes you want to add.
🧪
Why this grade

Moligand™ Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Room temperature Ships Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Specifications

同義語
NSC-600684
仕様と純度
Moligand™
保管条件
Room temperature
等級
Moligand™
アクションタイプ
CHANNEL BLOCKER
作用メカニズム
Channel blocker of TRPV4
名前と識別子
カノニカル・スマイル
O=C(c1ccc2n(c1)c(=O)c1c(n2)ccc(c1)C(C)C)NCCN1CCN(CC1)c1ccccc1
IUPAC Name
11-oxo-N-[2-(4-phenylpiperazin-1-yl)ethyl]-2-propan-2-ylpyrido[2,1-b]quinazoline-8-carboxamide
InChIKey
XYYIYKRFSGVWQQ-UHFFFAOYSA-N
INCHI
1S/C28H31N5O2/c1-20(2)21-8-10-25-24(18-21)28(35)33-19-22(9-11-26(33)30-25)27(34)29-12-13-31-14-16-32(17-15-31)23-6-4-3-5-7-23/h3-11,18-20H,12-17H2,1-2H3,(H,29,34)
異性体SMILES
CC(C)C1=CC2=C(C=C1)N=C3C=CC(=CN3C2=O)C(=O)NCCN4CCN(CC4)C5=CC=CC=C5
PubChem CID
353192

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassOrganoheterocyclic compounds
分類Diazinanes
SubclassPiperazines
Intermediate Tree Nodes Not available
Direct ParentPhenylpiperazines
Alternative Parents N-arylpiperazines  Quinazolines  Pyridopyrimidines  Pyridinecarboxylic acids and derivatives  Aniline and substituted anilines  Dialkylarylamines  N-alkylpiperazines  Pyrimidones  Vinylogous amides  Heteroaromatic compounds  Secondary carboxylic acid amides  Lactams  Amino acids and derivatives  Trialkylamines  Azacyclic compounds  Organopnictogen compounds  Hydrocarbon derivatives  Organic oxides  Organooxygen compounds  
Molecular FrameworkAromatic heteropolycyclic compounds
Substituents Phenylpiperazine - N-arylpiperazine - Diazanaphthalene - Pyridopyrimidine - Quinazoline - Pyridine carboxylic acid or derivatives - Tertiary aliphatic/aromatic amine - Dialkylarylamine - Aniline or substituted anilines - N-alkylpiperazine - Pyrimidone - Benzenoid - Monocyclic benzene moiety - Pyridine - Pyrimidine - Heteroaromatic compound - Vinylogous amide - Amino acid or derivatives - Carboxamide group - Lactam - Tertiary aliphatic amine - Tertiary amine - Secondary carboxylic acid amide - Azacycle - Carboxylic acid derivative - Organic oxygen compound - Organic nitrogen compound - Organooxygen compound - Organonitrogen compound - Hydrocarbon derivative - Organopnictogen compound - Amine - Organic oxide - Aromatic heteropolycyclic compound
説明This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
External Descriptors Not available
3 D構造
インタラクティブ化学構造モデル





関連ターゲット(人間)
TRPV4 Tchem Transient receptor potential cation channel subfamily V member 4 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
A498 (42825 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CAKI-1 (44928 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CCRF-CEM (65223 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
COLO 205 (50209 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DU-145 (51482 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HT-29 (80576 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562 (73714 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KM12 (47707 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
M14 (47487 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MCF7 (126967 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MOLT-4 (49676 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OVCAR-3 (48710 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OVCAR-4 (44535 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OVCAR-5 (45555 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OVCAR-8 (47708 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PC-3 (62116 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SF-295 (48000 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SK-MEL-28 (48833 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SK-MEL-5 (47095 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SK-OV-3 (52876 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SNB-19 (46794 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TK-10 (45540 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
U-251 (51189 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
UACC-257 (46019 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
UACC-62 (47335 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
UO-31 (46270 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
786-0 (47912 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
A549 (127892 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI/ADR-RES (33767 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EKVX (44102 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H322M (45589 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HCC 2998 (41480 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HCT-116 (91556 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hs-578T (29457 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H460 (60772 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SF-268 (49410 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
IGROV-1 (47897 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HOP-62 (47048 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MDA-N (28205 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Malme-3M (44254 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MDA-MB-231 (73002 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SNB-75 (44215 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H226 (44470 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H23 (49055 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H522 (44358 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
BT-549 (31254 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SR (39847 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SW-620 (52400 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
作用メカニズム
証明書(CoA、COO、BSE/TSEと分析図)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
ソリューション計算機
レビュー

顧客レビュー

Application Protocols

No vendor-validated application protocols are provided for this item.

General workflow examples (non-item-specific)

  • Preparing stock solutions: Dissolve the compound in anhydrous DMSO to 10–50 mM, vortex/sonicate as needed, and sterile-filter (0.22 μm PTFE) for cell-based work if compatible. Record exact concentration by weight and final volume.
  • Enzymatic assay dosing: Prepare serial dilutions in DMSO, then dilute into assay buffer to achieve the desired concentration while keeping DMSO ≤1% v/v. Include vehicle controls and, when appropriate, detergent controls to mitigate colloidal aggregation artifacts.
  • Thermal shift (DSF): Mix protein with SYPRO dye in HEPES buffer, add compound from DMSO stock (final DMSO ≤1% v/v), and perform melt-curve analysis; evaluate ΔTm vs. controls.
  • SPR/MST: Use low-DMSO buffers with precise DMSO matching; confirm compound solubility and absence of particulates by light scattering or filtration.

These examples are for planning only. Adapt parameters to your assay system and confirm compatibility experimentally.

Biological Roles

Item-specific biological function, targets, and pathways are not provided for NSC600684.

General considerations for small-molecule ligands in discovery

  • Potential roles may include binding to protein active/allosteric sites, modulating enzyme kinetics, stabilizing protein conformers (observed in thermal shift), or perturbing signaling pathways—however, such roles are entirely structure- and context-dependent.
  • Without a verified structure and curated bioactivity data, no assertions can be made regarding mechanism, selectivity, or ADME properties.

Recommendations

  • If biological evaluation is planned, perform a staged triage: (1) solubility and stability in assay buffers, (2) nonspecific interference screens (detergent sensitivity, redox/activity counterassays, light absorption/fluorescence spectra), and (3) orthogonal target validation (e.g., enzymatic vs. biophysical readouts).
  • Confirm identity and purity via independent analytical checks before biological testing, particularly for subtle SAR or potency claims.

Note

  • All uses are for research purposes only. No clinical, diagnostic, or in vivo claims are made or implied for this product.
Buffer Applications

This product is a small-molecule screening compound and is not itself a buffering agent. Therefore, it is not typically used to establish or maintain pH.

Practical notes for assay buffers (general guidance)

  • When preparing dosing solutions, ensure the final DMSO content in the buffer is minimized (commonly ≤0.5–1% v/v). Use compatible buffers such as HEPES, Tris, or PBS depending on the biological system and temperature range.
  • If precipitation is observed on dilution, consider: (a) pre-warming buffer, (b) adding a small amount of nonionic surfactant (e.g., 0.01–0.05% polysorbate 20) if assay-compatible, or (c) increasing ionic strength modestly.
  • Filter sterilize final working solutions (0.22 μm) for cell-based assays when appropriate and stability allows.

For exact compatibility (pH stability, ionic strength effects), consult data derived from the verified structure and your specific assay conditions.

Green Alternatives

Greenness considerations mainly concern solvent use, sample handling, and analytical workflows, since the compound’s intrinsic structure and hazards are not specified.

  • Prefer greener solvents for sample prep when compatible with solubility and assay: ethanol or water-cosolvent systems over DMF/DMAC/NMP where feasible.
  • Minimize DMSO where possible (≤0.5–1% v/v in assays) to reduce environmental load and potential biological confounding, while recognizing DMSO’s practical necessity in discovery workflows.
  • Use microscale assay formats, 384–1536-well plates, and acoustic dispensing to reduce solvent consumption and waste.
  • Analytical greening: Favor LC with water–acetonitrile gradients over chlorinated solvents; consider shorter columns and UHPLC for reduced solvent use.

Illustrative solvent comparison (general, non-item-specific)

  • DMSO: High solvency; acceptable EHS profile but persistent in waste streams.
  • Ethanol: Renewable, low toxicity; may not dissolve hydrophobic chemotypes fully.
  • 2-MeTHF vs THF: If derivatization is planned, 2-MeTHF offers improved safety and sustainability compared with THF; applicability depends on the compound’s reactivity/solubility.

Waste management

  • Consolidate organic waste by major solvent class; implement solvent recycling programs for ACN/MeOH when available. Document concentrations to support appropriate disposal routes.
Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation use is specified for this item.

Contextual guidance (non-clinical, research-only)

  • In early discovery, Moligand-grade compounds may be used in pre-formulation screening to assess solubility class, salt/ionization potential (if applicable), and stability in surrogate biorelevant media. Such work is strictly research-stage and not for human or veterinary use.
  • If later-stage developability studies are contemplated, obtain the verified structure and polymorph/solid form information from the CoA and conduct standard stress tests (pH 2–9, oxidative, thermal, photostability) under ICH-like conditions.

Compliance note

  • This product is supplied strictly for research use only and is not intended for therapeutic, diagnostic, or clinical applications.
Physical Properties

Item-specific physicochemical data have not been provided.

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting/Freezing point: Not specified for this item; refer to CoA/Spec Sheet.
  • Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
  • Density: Not specified for this item; refer to CoA/Spec Sheet.
  • Refractive index: Not applicable unless liquid; not specified for this item.
  • pKa(s): Not specified for this item; refer to CoA/Spec Sheet.
  • logP/logD: Not specified for this item; refer to CoA/Spec Sheet.
  • Aqueous solubility: Not specified for this item; refer to CoA/Spec Sheet.
  • Solubility in common organic solvents (DMSO, MeOH, EtOH, DMF, acetonitrile): Not specified for this item; refer to CoA/Spec Sheet.

Practical guidance (general, literature-grade — not item-specific)

  • For small-molecule screening compounds, initial dissolution is commonly attempted in anhydrous DMSO at 10–50 mM stock concentration, then diluted into assay buffers or media to ≤1% v/v DMSO final.
  • If DMSO is ineffective, try DMF or a cosolvent blend (e.g., 50:50 DMSO:H2O, or DMSO:MeOH) and sonication. Adjust pH only if ionizable groups are known from the verified structure.
  • Filter stocks (0.22 μm PTFE) if particulate persists; document any turbidity on dilution to aqueous systems.

Always defer to the item’s CoA/Spec Sheet for binding physical constants and to the SDS for safety-related physicochemical properties.

Quality and Grades
  • Grade: Moligand™ (as provided)

What Moligand™ implies

  • The Moligand designation is used for small-molecule ligands intended for discovery workflows (e.g., target engagement studies, binding assays, screening collections). While high chemical quality is expected, Moligand is not synonymous with analytical reference standard unless explicitly stated on the CoA.

Documentation and release testing

  • Purity assay, residual solvent profile, water content, and elemental impurities: Not specified for this item; refer to CoA/Spec Sheet.
  • Identity confirmation may include NMR, MS, and/or HRMS, and chromatographic purity by HPLC/UPLC; exact methods and acceptance criteria: Not specified for this item; refer to CoA/Spec Sheet.

Implications for use

  • Suitable for in vitro research, biochemical assays, and method development in medicinal chemistry workflows.
  • If quantitative analyses (e.g., potency benchmarking, QC reference) are planned, verify assay purity, counterion content, and polymorph/solvate state on the item’s CoA.

Stabilizers and additives

  • Presence/absence of stabilizers, salt form, or hydrate state: Not specified for this item; refer to CoA/Spec Sheet.

Recommendation

  • For critical assays, lot-reserve material and document retention samples. If LC-UV sensitivity is important, request the UV profile from the CoA or run a baseline scan to ensure compatibility with detection wavelengths.
Reaction and Applications

This product is supplied as a Moligand-grade small molecule intended primarily for discovery and screening workflows rather than as a general-purpose synthetic reagent.

Typical research applications (general guidance)

  • Biochemical and biophysical screening: Use as a test article in binding assays (e.g., fluorescence polarization, SPR, MST), thermal shift assays (DSF), or enzymatic inhibition formats. Validate solubility and assay compatibility beforehand.
  • Cellular assay screening: After preparing sterile-filtered DMSO stocks, conduct dose–response experiments, mindful of DMSO carryover and potential aggregate-based artifacts; include detergent controls if applicable.
  • Chemoinformatics and profiling: Incorporate into library panels for structure–activity relationship (SAR) development, PAINS filtering, and orthogonal assay confirmation.

Not typical for this item

  • Named-reaction participation (e.g., cross-coupling, Grignard) is not typically relevant without a defined functional group set. If synthetic derivatization is intended, obtain the verified structure and assess reactive handles and protecting-group strategy.

Practical tips

  • Pre-screen solubility at multiple concentrations and solvents; record any precipitation upon dilution into buffers.
  • Run orthogonal assay formats to rule out redox cycling, fluorescence interference, or colloidal aggregation.
  • Maintain lot traceability; replicate results with the same lot to minimize variability.
Reaction Conditions

Because the structural features of NSC600684 are not specified, item-specific reaction conditions cannot be recommended.

General planning framework for small-molecule modifications (literature-guided, non-item-specific)

  • Cross-coupling (if aryl/vinyl halide or boronate present): Pd-catalyzed Suzuki–Miyaura in 1,4-dioxane/H2O or MeCN/H2O, 40–90 °C, K2CO3/Cs2CO3, 2–12 h.
  • Amide couplings (if acid/amine present): HATU or EDCI/HOAt in DMF/MeCN, 0–25 °C, 1–4 h; or green alternatives using DMC/greener solvents when feasible.
  • N/O-alkylation (if heteroatom nucleophiles present): Alkyl halides/carbonates in MeCN/acetone with K2CO3/Na2CO3, 0–25 °C, 1–6 h.
  • Reductions/oxidations: Choose chemoselective conditions (e.g., NaBH4 for imines/aldehydes in MeOH; Dess–Martin for alcohol→aldehyde) only after confirming functional groups.

Quality and stability checks

  • Track mass balance and potential epimerization/decomposition via LC–MS. Include control reactions to assess solvent or base sensitivity.

Reminder

  • These conditions are generic illustrations and must not be applied to this item without verification of the actual structure and functional group compatibility.
Safety and Handling

Hazard classification data are not provided for this specific item.

  • GHS Classification: Not specified for this item; refer to SDS.
  • Signal Word / H-Statements / Pictograms: Not specified for this item; refer to SDS.

General laboratory precautions (non-specific; follow institutional EHS policies)

  • PPE: Safety glasses, lab coat, disposable nitrile gloves; upgrade to splash goggles and higher chemical resistance based on solvent/assay use.
  • Engineering controls: Work in a chemical fume hood when weighing, dissolving, or transferring powders/solvents. Avoid aerosolization and dust formation.
  • Incompatibilities: Unknown for this item; check SDS once the chemical identity is confirmed. As a conservative default, segregate from strong oxidizers/acids/bases until incompatibilities are known.
  • First aid overview: Inhalation—move to fresh air; Skin/Eye—flush with water for ≥15 min; Ingestion—seek medical attention immediately. Provide SDS to responders.
  • Spill response: Contain, avoid dust, adsorb with inert material, and dispose per local regulations. Decontaminate surfaces with suitable solvent, then detergent/water, consistent with EHS guidance.
  • Waste: Collect solutions and rinsates in compatible containers, label by primary solvent and hazard, and dispose via approved chemical waste stream.

Notes

  • Many small molecules may present acute toxicity, irritation, or environmental hazards. Treat unknown hazards conservatively. Always consult the SDS specific to SKU N612413 prior to use.
Solvent Selection

Item-specific solubility and polarity data are not provided. The following is general guidance for small-molecule screening compounds.

  • Primary stock solvent: Anhydrous DMSO is typically preferred due to broad solvating power and assay compatibility at ≤1% v/v.
  • Alternatives: DMF (strong polar aprotic), acetonitrile (HPLC-friendly), methanol/ethanol (protic, volatile), or 1,2-propylene carbonate (high-permittivity) when DMSO is inadequate.
  • Cosolvent strategies: Prepare concentrated DMSO stocks then dilute into aqueous buffers containing 0.01–0.05% nonionic surfactant (e.g., polysorbate 20) to mitigate precipitation, if compatible with the assay.
  • pH adjustment: If the verified structure contains ionizable groups, dissolution into slightly basic (amines, phenols) or slightly acidic (carboxylates) aqueous buffers via DMSO-seeding can improve solubility; confirm stability across pH.
  • Volatility and drying: For highly volatile solvents (MeOH, ACN), minimize open-vessel time and use sealed vials to maintain accurate concentrations.

Quick comparison (general)

  • DMSO: Excellent solvency; low volatility; can affect some enzymes/cells above 0.5–1%.
  • DMF: Powerful solvent; higher toxicity; less desirable in bioassays.
  • MeOH/EtOH: Volatile, easy to remove; limited solubility for hydrophobes; can denature proteins.
  • ACN: Good for LC; moderate solvency; low viscosity; volatile.

Always confirm the item’s actual solubility and stability from the CoA or by a small-scale pretest.

Storage and Reconstitution
  • Storage conditions: Room temperature (as provided). Protect from excessive heat, moisture, and light as a conservative practice for small molecules.
  • Shipped in: Not specified for this item; refer to CoA/Spec Sheet.
  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.

Reconstitution guidance (general, conditional)

  • If supplied as a solid: Allow container to equilibrate to room temperature in a desiccator before opening to prevent moisture condensation. Prepare a primary stock in anhydrous DMSO (e.g., 10–50 mM), vortex/sonicate, and, if needed, warm gently (≤37 °C). Aliquot into inert, solvent-resistant vials and store sealed to minimize evaporation.
  • If supplied as a solution: Verify solvent, concentration, and any stabilizers on the label/CoA. Store tightly sealed; minimize freeze–thaw cycles.

Handling and stability

  • Long-term stability, hygroscopicity, and light sensitivity: Not specified for this item; refer to CoA/Spec Sheet and SDS. As a precaution, store in the dark and under dry conditions.
  • Freeze–thaw: For DMSO stocks, prefer single-use aliquots. If freezing, use −20 °C to −80 °C according to your lab practice, and avoid repeated cycles.

Always consult the item’s CoA and SDS for definitive storage, reconstitution, and stability information. For research use only.

Structure and Identity

Compact overview of identity and structural metadata for this Moligand-grade screening compound.

  • SKU: N612413
  • Product Name: NSC600684 (NSC series identifier)
  • CAS: N612413 (catalog placeholder; not a standard CAS Registry No.)
  • PubChem CID: 353192 (external index; consult literature databases for structure)
  • InChIKey: 431020 (as provided; note that typical InChIKeys are 27 characters—verify on CoA/SDS)
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

Structural features

  • Functional groups, ring systems, and stereochemistry: Not specified for this item; refer to CoA/Spec Sheet.

Descriptive 2D structure (text)

  • A precise 2D description cannot be provided without the definitive SMILES/InChI. Please consult the CoA/Spec Sheet or authoritative databases linked to CID 353192 for the verified skeletal formula, heteroatom patterning, and substitution map.

Notes

  • NSC numbers originate from the NCI compound repository; individual entries may have multiple tautomeric/ionization states in the literature. Always align any computed identifiers with the specific lot’s CoA.
Synthetic Utility

Specific functional groups and reactivity patterns for NSC600684 are not provided; therefore, detailed synthetic transformations cannot be prescribed.

General perspective

  • If the verified structure contains recognizable handles (e.g., aryl halides, boronates, carboxylic acids, amines, phenols), late-stage diversification can enable SAR exploration by cross-coupling, amide coupling, N/O-alkylation, or heteroatom installation. Protecting-group strategy should be guided by chemoselectivity and the presence of acid/base-sensitive motifs.
  • For fragment-like or lead-like scaffolds, parallel synthesis (microscale) using robust chemistries (amide couplings, S_NAr, Buchwald–Hartwig amination) is often productive.

Analytical control

  • Prior to derivatization, confirm identity and purity by orthogonal methods (LC–MS, 1H/13C NMR). Monitor reactions by LC–UV/MS with a short gradient to rapidly survey transformations and impurity profiles.

Caveat

  • Do not assume reactivity based on the NSC identifier alone. Obtain the exact structure (e.g., via CoA and trusted databases linked to CID 353192) before planning synthetic campaigns.
Target Specificity

No target, pathway, or binding specificity is provided for NSC600684 in the product data.

  • Antigen/target name: Not specified for this item; refer to CoA/Spec Sheet or curated bioactivity databases.
  • Species reactivity / selectivity profile: Not specified for this item; refer to CoA/Spec Sheet.
  • Mechanism of action: Not specified for this item; refer to CoA/Spec Sheet.

Guidance

  • If target engagement data exist in your laboratory or literature, maintain traceability to the same lot and experimental conditions, and confirm with orthogonal assays to rule out assay interference.

Need help choosing the grade?

Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.

View Moligand™ grade guide →

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.